Beyond an infection.
These infections can complicate treatment, prolong hospital stays and negatively affect patient recovery and wellbeing.


An innovation by Arovia Medical

Better catheter care starts with better prevention.
Early-stage concept · Under development01 / The challenge
Catheter-associated urinary tract infections (CAUTIs) remain a significant challenge to patient safety and healthcare systems worldwide.
These infections can complicate treatment, prolong hospital stays and negatively affect patient recovery and wellbeing.
CAUTIs place additional demands on clinical staff, hospital resources and healthcare expenditure, highlighting the need for improved preventative solutions.
Despite advances in infection prevention, CAUTIs remain an important concern in healthcare settings where urinary catheterisation is routinely required.
The scale of the challenge
Catheters can be essential to care. Infection can turn that necessary support into additional illness, treatment and time in hospital.
15–25%
receive a urinary catheter during their stay, according to the US CDC.
CDC · Hospital context [1] ↗~75%
are associated with a urinary catheter, according to the US CDC. This is not the proportion of catheter users who develop infection.
CDC · Hospital context [1] ↗3–7%
with an indwelling catheter. Bacteriuria means bacteria in urine; it is not the same as a symptomatic CAUTI.
CDC · Colonisation, not infection [2] ↗Pressure on UK care
A historical NHS cost estimate for CAUTI cited in NHS England’s 2019 urology handbook, alongside an estimated £1,968 per episode. These are historical figures, not a current valuation or a forecast of CatheSafe savings. [3]
More than a financial cost
CAUTIs are associated with longer hospital stays, increased illness and higher care costs. Treating symptomatic infection requires antibiotics; avoiding unnecessary treatment of symptom-free bacteriuria is also important for antimicrobial stewardship. [1] [2]
The human impact
Published accounts make the consequences tangible: disrupted recovery, repeated hospital care and the anxiety of another infection.
When the journey home becomes a return to hospital.
In the linked CAUTI educational account, Jerri develops a urinary infection after hip-replacement surgery and catheterisation. She later returns to hospital with a surgical-site infection. The story illustrates how complications can disrupt an anticipated recovery.
An educational patient narrative, not evidence of how often this sequence occurs or proof that every later complication is caused by CAUTI.
Watch Jerri’s CAUTI story ↗The burden continues beyond a hospital admission.
In her interview with Sepsis Research FEAT, Amani describes needing catheters after an injury caused neurogenic bladder. At the time of the account, she reported four episodes of urosepsis, repeated hospital treatment and growing fear of recurrence.
Her experience also shows why awareness, being heard and connecting with others matter to people living with long-term catheter needs.
Read Amani’s story · Sepsis Research FEAT ↗Summaries of external published accounts, shared to explain the unmet need. Neither person is presented as a CatheSafe user or endorser. Individual experiences are not representative risk estimates; original accounts remain with their publishers.
Why better prevention matters
The potential value is broader than an infection count: fewer episodes of illness, less treatment burden and less pressure on care teams. These are goals for prevention, not demonstrated CatheSafe outcomes.
Preventing symptomatic infection could help avoid additional discomfort, treatment and disruption to everyday life.
Fewer infections could mean fewer antibiotic courses. Appropriate diagnosis remains essential: bacteria in urine alone do not usually require antibiotics. [2]
Reducing infection-related complications could help limit additional bed-days, clinical workload and costs. The size of any benefit must be measured. [1]
relative reduction in non-ICU CAUTI rates
A 2016 US programme across 603 hospitals combined safer catheter use and care with changes in team practices. Adjusted non-ICU rates fell from 2.28 to 1.54 infections per 1,000 catheter-days (incidence rate ratio 0.68; 95% CI 0.56–0.82). ICU rates were largely unchanged. [4]
This was a multifaceted improvement programme, not a CatheSafe trial. Its results cannot be used to predict CatheSafe’s effectiveness.
Established prevention includes appropriate catheter use, aseptic insertion, maintaining a closed drainage system and removing catheters when they are no longer needed. [1] CatheSafe is being developed with these care principles in mind; its safety, effectiveness, usability and economic value still require evaluation.
02 / The CatheSafe concept
Exploring a practical approach to catheter-associated infection prevention, built around the needs of patients and care teams.
CatheSafe is an early-stage infection-prevention device concept intended to be easily adoptable and fit into existing nursing workflows. Early nursing input and procurement perspectives are informing its development.
We are developing a novel medical device concept aimed at reducing the risk of catheter-associated urinary tract infections, with patient safety, clinical practicality and ease of adoption at the heart of our approach.
Discuss the research ↗03 / The CatheSafe vision
Meaningful medical innovation should address genuine clinical challenges while recognising the practical realities of delivering patient care.
Our vision is to develop accessible infection-prevention technology that could complement existing catheter-care practices without introducing unnecessary complexity for healthcare professionals.
By placing clinical needs, practical implementation and responsible development at the centre of our work, we aim to contribute to a future where catheter-associated infections are less burdensome for patients and healthcare systems.
04 / Our journey
Our development approach to infection prevention.
A roadmap for responsible innovation; milestones are not a record of completed approvals.
Establishing the fundamental scientific principles for rethinking infection prevention in catheter care.
Integrating clinical usability and nursing workflow perspectives to inform practical adoption.
Iterative testing and technical evaluation of device prototypes for responsible innovation.
Working towards regulatory review and clinical testing, with patient safety at the forefront.
Research, testing and regulatory review will determine the path ahead.
05 / Collaborate with us
CatheSafe welcomes conversations with clinicians, academic researchers, medical device specialists and organisations interested in the future of catheter-associated infection prevention.
Reviewed 15 November 2026. Estimates refer to different populations and publication periods; they should not be combined into a single risk estimate. US hospital figures are not presented as UK incidence data.
Hospital catheter use, catheter-associated share of hospital UTIs, burden and core prevention measures.
Daily bacteriuria incidence, distinction from symptomatic infection and the importance of avoiding unnecessary antibiotics.
Historical £99 million annual and £1,968 episode cost estimates. Not inflation-adjusted or presented as current expenditure.
926 units in 603 US hospitals; programme evaluation. Non-ICU improvement does not establish effectiveness of any particular device.
External educational narrative. The summary is not a product testimonial or an independent clinical case adjudication.
A first-person account of catheter use, recurrent urosepsis and its effects on daily life.
CatheSafe is an early-stage medical technology concept under development. It is not approved for clinical use or commercially available. Any proposed benefits remain subject to research, testing and regulatory review.